Effect analysis of irinotecan combined with raltitrexed regimen as second-line chemotherapy for advanced gastric cancer
WANG Qingbo
FENG Jifeng
LU Jianwei
LI Sheng
YANG Lili
Abstract：Objective To evaluate the recent efficacy and safety of irinotecan( CPT?11) plus raltitrexed as second?line regi?men for advanced gastric cancer. Methods Thirty?three patients with advanced gastric cancer were treated with CPT?11(200 mg/m2, 90 min, iv, d1) combined with raltitrexed(3 mg/m2, 15 min, iv, d1) regimen as second?line chemotherapy. Three weeks was a cycle. Response to chemotherapy was assessed by RECIST criteria 1?1 and toxicity was evaluated according to National Cancer Institute Com?mon Toxicity Criteria 4?0. The clinical follow?up data from chemotherapy were investigated. Results Thirty?three patients were all evaluable for recent efficacy and safety. There were no CR, 5 patients of PR, 16 patients of SD, and 12 patients of PD with the re?sponse rate of 15?2% and the disease control rate of 63?6%.The median progression?free survival was 3?3 months. The most common adverse reactions were anemia, nausea, vomiting, leucopenia, dysfunction of liver, delayed diarrhea, thrombocytopenia and constipa?tion, mainly in grade 1?2. Conclusion CPT?11 combined with raltitrexed is an effective and well?tolerated chemotherapy regimen as second?line treatment for advanced gastric cancer.
Keywords：RaltitrexedIrinotecan( CPT-11)Advanced gastric cancerSecond-line treatment
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 909-912 )